Imbruvica (ibrutinib) — United Healthcare

Initial criteria

• Diagnosis of Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Imbruvica therapy

Approval duration

12 months